Literature DB >> 15009715

BRAF mutations are common somatic events in melanocytic nevi.

Rajiv Kumar1, Sabrina Angelini, Erna Snellman, Kari Hemminki.   

Abstract

We determined mutations in the BRAF, N-ras, and CDKN2A genes in 27 histologically diverse melanocytic nevi and corresponding surrounding tissues from 17 individuals. Mutations in the BRAF and N-ras gene were found in 22 nevi (81%) from 16 individuals (94%). The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus had a novel A1781G (D594V) mutation in the same gene and 3 nevi had mutations in codon 61 of the N-ras gene. In 4 individuals both nevi carried a BRAF mutation, whereas in 2 other individuals 1 nevus showed a BRAF mutation and the second nevus had an N-ras mutation. In 2 individuals normal skin distant from nevi showed a BRAF mutation. No mutations were detected in the CDKN2A gene. The mutations in the BRAF and N-ras genes, in this study, were not associated with histologic type, location, skin type, size, or numbers of nevi. Our results suggest that mutations in the BRAF gene and to some extent in the N-ras gene represent early somatic events that occur in melanocytic nevi. We hypothesize the dual effect of solar ultraviolet irradiation on melanoma, through mutagenesis and by increasing the number of melanocytic nevi, many of which carry a BRAF or N-ras mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009715     DOI: 10.1046/j.0022-202X.2004.22225.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  50 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Molecular targets in melanoma: time for 'ethnic personalization'.

Authors:  Shane Y Morita; Svetomir N Markovic
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

3.  The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.

Authors:  Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

Review 4.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

Review 5.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

Review 6.  Mosaicism in Cutaneous Disorders.

Authors:  Young H Lim; Zoe Moscato; Keith A Choate
Journal:  Annu Rev Genet       Date:  2017-11-27       Impact factor: 16.830

7.  Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index.

Authors:  D M Berman; S Wincovitch; S Garfield; M J Romeo
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

8.  A prognostic signature of G(2) checkpoint function in melanoma cell lines.

Authors:  Bernard Omolo; Craig Carson; Haitao Chu; Yingchun Zhou; Dennis A Simpson; Jill E Hesse; Richard S Paules; Kristine C Nyhan; Joseph G Ibrahim; William K Kaufmann
Journal:  Cell Cycle       Date:  2013-03-01       Impact factor: 4.534

9.  There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis.

Authors:  Rolf K Swoboda; Meenhard Herlyn
Journal:  Exp Dermatol       Date:  2013-03-12       Impact factor: 3.960

10.  Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.

Authors:  Caroline Kannengiesser; Alain Spatz; Stefan Michiels; Alain Eychène; Philippe Dessen; Vladimir Lazar; Véronique Winnepenninckx; Fabienne Lesueur; Sabine Druillennec; Caroline Robert; Joost J van den Oord; Alain Sarasin; Brigitte Bressac-de Paillerets
Journal:  Mol Oncol       Date:  2008-01-12       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.